Tetraphase Pharmaceuticals Inc - Strategic SWOT Analysis Review
Tetraphase Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights
Tetraphase Pharmaceuticals Inc (Tetraphase), a subsidiary of La Jolla Pharmaceutical Company, is a pharmaceutical company that discovers and develops antibiotic resistance medicines. The company’s products under clinical development include Xerava (eravacycline), TP-271, TP-2846 and TP-6076. It develops products for the treatment of respiratory diseases caused by bacterial biothreat and antibiotic resistant public health pathogens. Tetraphase’s eravacycline is used for the treatment of multi-drug resistant (MDR) infections which include MDR gram-negative bacteria. The company offers drugs in therapeutic areas of antibiotics, oncology and inflammatory diseases. It also offers research and creation of tetracycline drugs. Tetraphase is headquartered in Waltham, Massachusetts, the US.
Tetraphase Pharmaceuticals Inc Key Recent Developments
May 07,2020: Tetraphase Pharmaceuticals reports first quarter 2020 financial results and highlights recent corporate developments
Apr 22,2020: Tetraphase Pharmaceuticals receives loan under Paycheck Protection Program
Mar 17,2020: Tetraphase Pharmaceuticals to merge with AcelRx
Mar 12,2020: Tetraphase Pharmaceuticals reports fourth quarter and full-year 2019 financial results and highlights achievements and key 2020 milestones
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.